Search

Your search keyword '"İdilman, R."' showing total 464 results

Search Constraints

Start Over You searched for: Author "İdilman, R." Remove constraint Author: "İdilman, R."
464 results on '"İdilman, R."'

Search Results

1. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

2. A global research priority agenda to advance public health responses to fatty liver disease

3. The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

4. Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

5. SARS-CoV-2 vaccination and risk of severe COVID-19 outcomes in patients with autoimmune hepatitis

6. Global multi-stakeholder endorsement of the MAFLD definition

8. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

9. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

10. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis

11. Advancing the global public health agenda for NAFLD: a consensus statement

13. Predictors of clinical response: results from a large, randomized controlled study with Tenofovir Disoproxil Fumarate (TDF) plus Peginterferon alfa-2A (PEG) combination for chronic hepatitis B (CHB)

15. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B

16. Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B

17. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study

18. Outcome of COVID-19 in patients with autoimmune hepatitis: an international multi-centre study

19. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study

20. Strategies to manage hepatitis C virus (HCV) disease burden

21. The present and future disease burden of hepatitis C virus (HCV) infection with todayʼs treatment paradigm

22. Historical epidemiology of hepatitis C virus (HCV) in selected countries

24. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

25. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B

26. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B

34. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

41. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population

42. Häufigkeit, Schwere und Konsequenz von PEG-IFNa-assoziierten Flares bei einer HDV-Infektion

43. Health-related Quality of Life of Liver Donors: A Prospective Longitudinal Study

47. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B

48. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study

49. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy

50. Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort

Catalog

Books, media, physical & digital resources